Defilade Capital Management, L.P.
About Defilade Capital Management, L.P.’s 13F portfolio
Defilade Capital Management, L.P. is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Defilade Capital Management, L.P. reported $746.9M across 39 US-listed positions (). Its largest position is ELI LILLY & CO (LLY) at 6.3% of the reported book, and its ten biggest holdings make up 47% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NYSE: LLY ELI LILLY & CO | — — | 6.3% | 39K | $46.9M |
| 2 | NYSE: PFE PFIZER INC | — — | 5.7% | 1.8M | $42.7M |
| 3 | NYSE: VEEV VEEVA SYS INC | — — | 5.6% | 237K | $42.0M |
| 4 | NASDAQ: BMRN BIOMARIN PHARMACEUTICAL INC | — — | 5.2% | 682K | $39.0M |
| 5 | NASDAQ: PTCT PTC THERAPEUTICS INC | — — | 4.7% | 434K | $35.4M |
| 6 | NYSE: BAX BAXTER INTL INC | — — | 4.2% | 1.5M | $31.1M |
| 7 | NASDAQ: INSM INSMED INC | — — | 4.0% | 282K | $30.0M |
| 8 | NYSE: ZBH ZIMMER BIOMET HOLDINGS INC | — — | 3.7% | 317K | $27.3M |
| 9 | NASDAQ: PODD INSULET CORP | — — | 3.6% | 177K | $26.9M |
| 10 | NYSE: TMO THERMO FISHER SCIENTIFIC INC | — — | 3.5% | 52K | $26.0M |
| 11 | NYSE: ABT ABBOTT LABORATORIES | — — | 3.5% | 286K | $25.9M |
| 12 | NASDAQ: ASND ASCENDIS PHARMA A/S | — — | 3.4% | 95K | $25.3M |
| 13 | NYSE: SOLV SOLVENTUM CORP | — — | 3.3% | 316K | $24.4M |
| 14 | NYSE: MDT MEDTRONIC PLC | — — | 3.2% | 303K | $23.7M |
| 15 | NYSE: ELAN ELANCO ANIMAL HEALTH INC | — — | 2.8% | 864K | $21.3M |
| 16 | NASDAQ: AGIO AGIOS PHARMACEUTICALS INC | — — | 2.7% | 547K | $20.3M |
| 17 | NYSE: NVST ENVISTA HOLDINGS CORPORATION | — — | 2.6% | 726K | $19.1M |
| 18 | NASDAQ: RVMD REVOLUTION MEDICINES INC | — — | 2.1% | 83K | $15.5M |
| 19 | NASDAQ: ICUI ICU MED INC | — — | 2.1% | 106K | $15.5M |
| 20 | NASDAQ: COGT COGENT BIOSCIENCES INC | — — | 2.0% | 393K | $15.2M |
| 21 | NASDAQ: LNTH LANTHEUS HLDGS INC | — — | 2.0% | 133K | $14.7M |
| 22 | NASDAQ: OCUL OCULAR THERAPEUTIX INC | — — | 2.0% | 1.5M | $14.6M |
| 23 | NASDAQ: ELDN ELEDON PHARMACEUTICALS INC | — — | 1.9% | 3.5M | $13.9M |
| 24 | NASDAQ: TYRA TYRA BIOSCIENCES INC | — — | 1.6% | 377K | $12.0M |
| 25 | NASDAQ: OLMA OLEMA PHARMACEUTICALS INC | — — | 1.5% | 925K | $11.6M |
Showing 1–25 of 39 positions on this page reported in this 13F.
- Healthcare100%
- AddedLLYELI LILLY & CO+88.9%$46.9M
- AddedPFEPFIZER INC+21.0%$42.7M
- NewVEEVVEEVA SYS INC—$42.0M
- NewBMRNBIOMARIN PHARMACEUTICAL INC—$39.0M
- AddedPTCTPTC THERAPEUTICS INC+15.3%$35.4M
- NewBAXBAXTER INTL INC—$31.1M
- AddedINSMINSMED INC+44.6%$30.0M
- NewPODDINSULET CORP—$26.9M
- NewTMOTHERMO FISHER SCIENTIFIC INC—$26.0M
- NewABTABBOTT LABORATORIES—$25.9M
- ReducedZBHZIMMER BIOMET HOLDINGS INC−45.2%$27.3M
- ReducedELANELANCO ANIMAL HEALTH INC−7.2%$21.3M
- ReducedRVMDREVOLUTION MEDICINES INC−73.8%$15.5M
- ReducedICUIICU MED INC−58.4%$15.5M
- ReducedLNTHLANTHEUS HLDGS INC−46.8%$14.7M
- ReducedELDNELEDON PHARMACEUTICALS INC−1.1%$13.9M
- ReducedOLMAOLEMA PHARMACEUTICALS INC−38.5%$11.6M
- ReducedGMEDGLOBUS MED INC−60.6%$11.0M
- ReducedDNLIDENALI THERAPEUTICS INC−71.2%$10.1M
- ReducedPACSPACS GROUP INC−64.3%$9.2M
Reading Defilade Capital Management, L.P.’s 13F portfolio
Defilade Capital Management, L.P.’s $746.9M 13F book is spread across 39 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 47%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are LLY, PFE, VEEV, BMRN and PTCT, led by ELI LILLY & CO (LLY) at 6.3% of the portfolio. The heaviest sector exposure is Healthcare (100%).
What Defilade Capital Management, L.P. changed last quarter
Between 2026-03-31 and Q2 2026, Defilade Capital Management, L.P. was a net buyer: it opened 20 new positions and added to 8 more, while trimming 10 and closing 12 outright. Against a 39-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ELI LILLY & CO (LLY), and its biggest reduction was ZIMMER BIOMET HOLDINGS INC (ZBH).
What a 13F does and doesn’t reveal
A 13F captures only Defilade Capital Management, L.P.’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Defilade Capital Management, L.P. is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Defilade Capital Management, L.P.'s profile on this page is built directly from those filings.
How current is the 13F data on Defilade Capital Management, L.P.'s page?
It reflects Defilade Capital Management, L.P.'s most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Defilade Capital Management, L.P. files its next quarterly report, this page refreshes automatically.
Can I see Defilade Capital Management, L.P.'s complete list of holdings?
This page highlights Defilade Capital Management, L.P.'s largest positions rather than all 39 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Defilade Capital Management, L.P.'s filings.
Does a 13F show everything Defilade Capital Management, L.P. owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Defilade Capital Management, L.P.'s book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Defilade Capital Management, L.P. made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

